OrbiMed’s Genfit GNFT Stock Holding History

OrbiMed’s Portfolio GNFT Stock Details GNFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,125,607	Closed	-$22.2M	–	130
2019 Q2	$22.2M	Sell	1,125,607 -104,707	-9%	-$2.45M	0.34%	67
2019 Q1	$29.5M	Buy	+1,230,314	New	+$28.4M	0.46%	55

Other funds holding GNFT

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OGC

One68 Global Capital New York $30.9M AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

OrbiMed's GNFT Position: Q3 2019 in Review

OrbiMed sold out of Genfit (GNFT) in Q3 2019, closing a stake of 1,125,607 shares — an estimated $22.2M sold.

OrbiMed first reported a position in GNFT in Q1 2019 and held it in 2 quarters. The position peaked at $29.5M in Q1 2019. 18 funds tracked by Wall St. Rank hold GNFT as of Q3 2019.

OrbiMed reported no remaining Genfit position as of Q3 2019 after selling out during the quarter.
OrbiMed sold 1,125,607 Genfit shares in Q3 2019, an estimated $22.2M.
OrbiMed first reported a position in Genfit in Q1 2019 and held it in 2 quarters.
OrbiMed's Genfit position peaked at $29.5M in Q1 2019.
18 funds tracked by Wall St. Rank held Genfit as of Q3 2019.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.